查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1338910

促紅血球生成素製劑市場、份額、規模、趨勢、產業分析報告:按產品、按類型、按應用、按地區、按細分市場、預測2023-2032

Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，到 2032 年，全球促紅血球生成素市場預計將達到 76.5 億美元。該報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

貧血是世界主要的健康問題，而促紅血球生成素製劑是主要的治療方法。根據 CDC 的慢性腎臟病指南，估計美國 15% 的成年人（即 3,700 萬人）患有 CKD。慢性腎臟病在老年人中比 45 至 64 歲 (13%) 和 18 至 44 歲 (7%) 更常見。此外，對替代品牌藥物的廉價生物相似藥的需求不斷增加，預計將增加對促紅血球生成素製劑的需求。

北美地區促紅血球生成素製劑的採用率高於其他地區。這是由於多種因素造成的，包括貧血和慢性腎臟病的高盛行率、先進的醫療基礎設施以及大型製藥公司的存在。

此外，有利的政府政策和報銷制度也促進了促紅血球生成素產品在北美的廣泛使用。例如，在美國，醫療保險涵蓋末期腎病患者的促紅血球生成素治療，大大增加了患者獲得促紅血球生成素產品的機會。

你有任何問題嗎？您想在購買此報告之前索取樣品或進行詢價嗎？

2023 年2 月，GSK生產的JessDuBroke 片劑獲得美國食品和藥物管理局批准，成為首個口服治療藥物，用於治療因慢性腎臟病而患有貧血並接受透析四個月或更長時間的成人。這項批准代表了慢性腎臟病引起的貧血治療的重大突破，為以前不得不依賴注射促紅血球生成素的患者提供了更簡單、更容易獲得的治療選擇。

2022年11月，英國國家醫療服務體系實現了突破，進行了世界上首次輸注由供體細胞培養的紅血球。這項科學裡程碑可能為罕見血型患者的治療開闢新途徑。

促紅血球生成素製劑市場報告亮點

生物製品領域主導市場並佔收入的很大一部分。受歡迎的產品包括 Procrit、Neolecolmon、Epogin、Mircera、Aranesp 和 Epogen。

到2022年，促紅血球生成素細分市場將佔據最大的市場份額。依泊汀-BETA 在維持血液透析患者的血紅素水平方面優於依泊汀-ALPHA，因此預計未來會出現正增長。

2022年，腎臟病細分市場將佔據最大市場份額，腎臟移植及相關疾病報銷政策的製定也正在推動該細分市場的發展。

北美在市場上佔據主導地位，由於藥物先驅的存在、CKD 患者的醫療保險覆蓋以及 FDA 對 Epogen、Aranesp 和 Procrit Masu 等藥物的批准，預計在預測期內將以最高的複合年增長率增長。

目錄

第 1 章 簡介

第二章執行摘要

第三章研究方法論

第四章全球促紅血球生成素藥物市場洞察

  • 促紅血球生成素製劑市場 - 產品概況
  • 促紅血球生成素製劑市場動態
    • 驅動因素和機遇
      • 慢性病發病率增加
      • 紅血球生成刺激劑 (ESA) 的超說明書使用
    • 限制因素和挑戰
      • 品牌湧入
  • PESTEL 分析
  • 促紅血球生成素藥物市場的產品趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球促紅血球生成素製劑市場（按類型）

  • 主要發現
  • 介紹
  • 生物製劑
  • 生物相似藥

第六章全球促紅血球生成素藥物市場（依應用）

  • 主要發現
  • 介紹
  • 癌症
  • 腎臟疾病
  • 神經病學
  • 其他

第七章全球促紅血球生成素製劑市場，依產品

  • 主要發現
  • 介紹
  • 促紅細胞生成素
  • 達貝泊汀阿爾法

第八章全球促紅血球生成素製劑市場（按地區）

  • 主要發現
  • 介紹
    • 2019-2032年促紅血球生成素製劑市場評估（按地區）
  • 促紅血球生成素醫藥市場 - 北美
    • 北美:2019-2032 年促紅血球生成素製劑市場（按類型）
    • 北美:促紅血球生成素製劑市場（按產品），2019-2032
    • 北美:促紅血球生成素製劑市場，依應用分類，2019-2032
    • 促紅血球生成素製劑市場－美國
    • 促紅血球生成素藥品市場－加拿大
  • 促紅血球生成素藥物市場－歐洲
    • 歐洲:2019-2032 年促紅血球生成素製劑市場（按類型）
    • 歐洲:促紅血球生成素製劑市場（依產品），2019-2032
    • 歐洲:促紅血球生成素製劑市場，依應用劃分，2019-2032
    • 促紅血球生成素藥品市場－英國
    • 促紅血球生成素製劑市場－法國
    • 促紅血球生成素製劑市場－德國
    • 促紅血球生成素製劑市場－義大利
    • 促紅血球生成素製劑市場－西班牙
    • 促紅血球生成素製劑市場－荷蘭
    • 促紅血球生成素製劑市場－俄羅斯
  • 促紅血球生成素藥物市場 - 亞太地區
    • 亞太地區:2019-2032 年促紅血球生成素製劑市場（按類型）
    • 亞太地區:促紅血球生成素製劑市場（依產品），2019-2032
    • 亞太地區:促紅血球生成素製劑市場，依應用劃分，2019-2032
    • 促紅血球生成素醫藥市場 - 中國
    • 促紅血球生成素藥品市場－印度
    • 促紅血球生成素藥品市場 - 馬來西亞
    • 促紅血球生成素製劑市場－日本
    • 促紅血球生成素藥品市場—印尼
    • 促紅血球生成素製劑市場－韓國
  • 促紅血球生成素製劑市場－中東和非洲
    • 中東和非洲:2019-2032 年促紅血球生成素製劑市場（按類型）
    • 中東和非洲:促紅血球生成素製劑市場（按產品），2019-2032
    • 中東和非洲:促紅血球生成素製劑市場，依應用劃分，2019-2032
    • 促紅血球生成素藥品市場－沙烏地阿拉伯
    • 促紅血球生成素製劑市場－阿拉伯聯合大公國
    • 促紅血球生成素製劑市場－以色列
    • 促紅血球生成素藥品市場－南非
  • 促紅血球生成素製劑市場－拉丁美洲
    • 拉丁美洲:2019-2032 年促紅血球生成素製劑市場（按類型）
    • 拉丁美洲:促紅血球生成素製劑市場，分產品，2019-2032
    • 拉丁美洲:促紅血球生成素製劑市場，依應用分類，2019-2032
    • 促紅血球生成素藥品市場—墨西哥
    • 促紅血球生成素藥品市場 - 巴西
    • 促紅血球生成素製劑市場－阿根廷

第9章 競爭格局

  • 擴張和收購分析
    • 擴張
    • 獲得
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • Amgen
  • Johnson & Johnson
  • Roche Ltd
  • Pfizer
  • Biocon
  • Teva Pharmaceutical
  • Kyowa Kirin
  • LG Life Sciences
  • AstraZeneca
  • Intas Pharmaceuticals
  • Shire
  • Sanofi
  • Novartis
  • Boehringer Ingelheim
  • Baxter International Inc.
Product Code: PM3354

The global erythropoietin drugs market size is expected to reach USD 7.65 billion by 2032, according to a new study by Polaris Market Research. The report "Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anemia is a major health concern globally, and Erythropoietin Drugs are the primary treatment for the condition. According to the CDC chronic kidney disease in the United States, 15% of adults in the USA, or 37 million people are estimated to have CKD. It is more common in old age population than in people aged 45-64 years (13%) and 18-44 years (7%). Moreover, the increasing demand for biosimilars, which are cheaper alternatives to branded drugs, is expected to drive the need for Erythropoietin Drugs.

Adoption of erythropoietin drugs is greater in North America compared to other regions. This is due to several factors such as the high prevalence of anemia and chronic kidney disease, the availability of advanced healthcare infrastructure, and the presence of a large number of major pharmaceutical companies in the region.

Additionally, favorable government policies and reimbursement schemes have also contributed to the widespread adoption of erythropoietin drugs in North America. For example, in the United States, Medicare provides coverage for erythropoietin therapy for patients with end-stage renal disease, which has significantly increased access to these drugs for patients in the country.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report?

In February 2023, Jesduvroq tablets, manufactured by GSK, received approval from the U.S. Food and Drug Administration as the first oral treatment option for adults suffering from anaemia due to chronic kidney disease and who have undergone dialysis for at least four months. This approval represents a significant breakthrough in the treatment of anaemia caused by chronic kidney disease, as it offers a more convenient and easily accessible treatment option for patients who previously had to rely on injectable erythropoietin drugs.

In November 2022, the UK's National Health Service made a ground-breaking achievement by performing the first-ever transfusion of lab-grown RBCs grown from the donor cells. This scientific milestone could open up new avenues for treating people with the rare blood types.

Erythropoietin Drugs Market Report Highlights

The biologics segment dominates the market, accounting for a significant share of revenue, with popular products including Procrit, NeoRecormon, Epogin, Mircera, Aranesp, and Epogen.

The erythropoietin segment holds the largest market share in 2022. Epoetin-beta is expected to grow positively in the future due to its superiority in maintaining hemoglobin concentration in hemodialysis patients over Epoetin-alfa.

The renal diseases segment holds the largest share of the market In 2022, due to developed reimbursement policies for renal transplants and related diseases are also driving this segment.

North America dominated the market and is expected to grow at a highest CAGR over the projected period because of the presence of organizations advancing drug development, Medicare coverage for CKD patients, and FDA approval of drugs like Epogen, Aranesp, and Procrit.

The global players include: Amgen, Johnson & Johnson, Roche, Pfizer, Biocon, and Teva Pharmaceutical.

Polaris Market Research has segmented the Erythropoietin Drugs market report based on type, product, application and region:

Erythropoietin Drugs, Type Outlook (Revenue, USD Billion, 2019 - 2032)

  • Biologics
  • Biosimilars

Erythropoietin Drugs, Product Outlook (Revenue, USD Billion, 2019 - 2032)

  • Erythropoietin
  • Darbepoetin-alfa

Erythropoietin Drugs, Application Outlook (Revenue, USD Billion, 2019 - 2032)

  • Cancer
  • Renal Diseases
  • Neurology
  • Others

Erythropoietin Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Erythropoietin Drugs Market Insights

  • 4.1. Erythropoietin Drugs Market - Product Snapshot
  • 4.2. Erythropoietin Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of chronic diseases
      • 4.2.1.2. Off-label use of Erythropoiesis stimulating agents (ESAs)
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Patent expiration of branded drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Erythropoietin Drugs Market Product Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Erythropoietin Drugs Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Biologics
    • 5.3.1. Global Erythropoietin Drugs Market, by Biologics, by Region, 2019-2032 (USD Billion)
  • 5.4. Biosimilars
    • 5.4.1. Global Erythropoietin Drugs Market, by Biosimilars, by Region, 2019-2032 (USD Billion)

6. Global Erythropoietin Drugs Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Cancer
    • 6.3.1. Global Erythropoietin Drugs Market, by Cancer, by Region, 2019-2032 (USD Billion)
  • 6.4. Renal Diseases
    • 6.4.1. Global Erythropoietin Drugs Market, by Renal Diseases, by Region, 2019-2032 (USD Billion)
  • 6.5. Neurology
    • 6.5.1. Global Erythropoietin Drugs Market, by Neurology, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Erythropoietin Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Erythropoietin Drugs Market, by Product

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • 7.3. Erythropoietin
    • 7.3.1. Global Erythropoietin Drugs Market, by Erythropoietin, By Region, 2019-2032 (USD Billion)
  • 7.4. Darbepoetin-alfa
    • 7.4.1. Global Erythropoietin Drugs Market, by Darbepoetin-alfa, By Region, 2019-2032 (USD Billion)

8. Global Erythropoietin Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Erythropoietin Drugs Market - North America
    • 8.3.1. North America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.3.3. North America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Erythropoietin Drugs Market - U.S.
      • 8.3.4.1. U.S.: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Erythropoietin Drugs Market - Canada
      • 8.3.5.1. Canada: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Erythropoietin Drugs Market - Europe
    • 8.4.1. Europe: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Erythropoietin Drugs Market - UK
      • 8.4.4.1. UK: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Erythropoietin Drugs Market - France
      • 8.4.5.1. France: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Erythropoietin Drugs Market - Germany
      • 8.4.6.1. Germany: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Erythropoietin Drugs Market - Italy
      • 8.4.7.1. Italy: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Erythropoietin Drugs Market - Spain
      • 8.4.8.1. Spain: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Erythropoietin Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Erythropoietin Drugs Market - Russia
      • 8.4.10.1. Russia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Erythropoietin Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Erythropoietin Drugs Market - China
      • 8.5.4.1. China: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Erythropoietin Drugs Market - India
      • 8.5.5.1. India: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Erythropoietin Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Erythropoietin Drugs Market - Japan
      • 8.5.7.1. Japan: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Erythropoietin Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Erythropoietin Drugs Market - South Korea
      • 8.5.9.1. South Korea: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Erythropoietin Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Erythropoietin Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Erythropoietin Drugs Market - UAE
      • 8.6.5.1. UAE: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Erythropoietin Drugs Market - Israel
      • 8.6.6.1. Israel: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Erythropoietin Drugs Market - South Africa
      • 8.6.7.1. South Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Erythropoietin Drugs Market - Latin America
    • 8.7.1. Latin America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Erythropoietin Drugs Market - Mexico
      • 8.7.4.1. Mexico: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Erythropoietin Drugs Market - Brazil
      • 8.7.5.1. Brazil: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Erythropoietin Drugs Market - Argentina
      • 8.7.6.1. Argentina: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Amgen
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Johnson & Johnson
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Roche Ltd
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Pfizer
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Biocon
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Teva Pharmaceutical
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Kyowa Kirin
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. LG Life Sciences
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. AstraZeneca
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Intas Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Shire
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Sanofi
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Novartis
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Boehringer Ingelheim
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Baxter International Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables

  • Table 1 Global Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 4 Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 8 U.S.: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 11 Canada: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 14 Europe: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 17 UK: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 20 France: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 23 Germany: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Italy: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 29 Spain: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 35 Russia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 41 China: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 44 India: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Japan: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 56 South Korea: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 65 UAE: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 68 Israel: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 71 South Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 74 Latin America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 77 Mexico: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 80 Brazil: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 83 Argentina: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Erythropoietin Drugs Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Erythropoietin Drugs Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Erythropoietin Drugs Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Product
  • Figure 11. Global Erythropoietin Drugs Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 12. Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Erythropoietin Drugs Market